{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:02:29Z","timestamp":1777874549386,"version":"3.51.4"},"reference-count":66,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of targeted agents in patients with advanced cancer and genomic alterations. Results of three cohorts of patients with colorectal cancer (CRC), breast cancer (BC), and other solid tumors (histology-pooled [HP]) with high tumor mutation burden (HTMB) treated with nivolumab plus ipilimumab (N + I) are reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Eligible patients had tumors with HTMB (\u226510 mutations per megabase), measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16 weeks duration. For histology-specific cohorts, Simon's two-stage design was based on a null DC rate of 15% versus 35% (power = 0.85; \u03b1 = .10). For the HP cohort, the hypothesized null DC rate of 15% was evaluated by a one-sided exact binomial test (\u03b1 = .10). Secondary end points were OR, progression-free survival, overall survival, duration of response, duration of SD, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Patients with CRC (N = 12), BC (N = 13), or other advanced cancers (N = 26) with HTMB were enrolled. The CRC cohort failed to reach the predetermined efficacy threshold to warrant expansion at the end of stage I. The BC cohort expanded to stage II but closed by company request before achieving the planned sample size. The DC rates (one-sided 90% CI) for BC and HP cohorts were 33% (15-100,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0976) and 32% (20-100), respectively. The null hypothesized 15% DC rate was rejected for the BC and HP cohorts but not the CRC cohort. Nineteen patients experienced treatment-related grade 3 adverse events (AE) or serious AEs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>N + I demonstrated antitumor activity in patients with tumors with HTMB in the BC and HP cohorts but not the CRC cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-25-01205","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:59:11Z","timestamp":1777579151000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study"],"prefix":"10.1200","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02693535","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-8611","authenticated-orcid":true,"given":"Erin F.","family":"Cobain","sequence":"first","affiliation":[{"name":"University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rothe","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-0333","authenticated-orcid":true,"given":"Elizabeth","family":"Garrett-Mayer","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5033-3071","authenticated-orcid":true,"given":"Timothy L.","family":"Cannon","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer Institute, Fairfax, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K.","family":"Chan","sequence":"additional","affiliation":[{"name":"Sutter Cancer Research Consortium, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-7743","authenticated-orcid":true,"given":"Kathryn F.","family":"Mileham","sequence":"additional","affiliation":[{"name":"Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bamidele","family":"Adesunloye","sequence":"additional","affiliation":[{"name":"City of Hope Atlanta, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen J.","family":"Calfa","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-4725","authenticated-orcid":true,"given":"Olatunji B.","family":"Alese","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3779-1886","authenticated-orcid":true,"given":"Kathleen Yost","family":"Butler","sequence":"additional","affiliation":[{"name":"Cancer Research Consortium of West Michigan, Grand Rapids, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7851-5165","authenticated-orcid":true,"given":"Elie G.","family":"Dib","sequence":"additional","affiliation":[{"name":"Michigan Cancer Research Consortium, Ypsilanti, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Pisick","sequence":"additional","affiliation":[{"name":"City of Hope Chicago, Zion, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Bell","sequence":"additional","affiliation":[{"name":"Sanford Health, Sioux Falls, SD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-8520","authenticated-orcid":true,"given":"Kelsey A.","family":"Klute","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inderjit","family":"Mehmi","sequence":"additional","affiliation":[{"name":"The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":true,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-6742","authenticated-orcid":true,"given":"Pam K.","family":"Mangat","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2052-9484","authenticated-orcid":true,"given":"Dominique C.","family":"Hinshaw","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-4369","authenticated-orcid":true,"given":"Abigail","family":"Gregory","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3111-0419","authenticated-orcid":true,"given":"Gina N.","family":"Grantham","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":true,"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4474-4303","authenticated-orcid":true,"given":"Richard L.","family":"Schilsky","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02508"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01679"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.154"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.1981"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.11181"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0450"},{"key":"e_1_3_11_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0458"},{"key":"e_1_3_11_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.008"},{"key":"e_1_3_11_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00702"},{"key":"e_1_3_11_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02923"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0327"},{"key":"e_1_3_11_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229"},{"key":"e_1_3_11_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407417"},{"key":"e_1_3_11_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008872"},{"key":"e_1_3_11_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.11.010"},{"key":"e_1_3_11_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01063"},{"key":"e_1_3_11_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59695-1"},{"key":"e_1_3_11_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"e_1_3_11_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01015"},{"key":"e_1_3_11_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402141"},{"key":"e_1_3_11_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0149"},{"key":"e_1_3_11_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104342"},{"key":"e_1_3_11_36_2","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.01.09"},{"key":"e_1_3_11_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30014-0"},{"key":"e_1_3_11_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.009"},{"key":"e_1_3_11_39_2","article-title":"Rationale and design of the targeted agent and profiling utilization registry study","author":"Mangat PK","unstructured":"Mangat PK, Halabi S, Bruinooge SS, et al: Rationale and design of the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/po.18.00122","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00752-8"},{"key":"e_1_3_11_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00753-7"},{"key":"e_1_3_11_42_2","article-title":"Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR Study","author":"Yang ES","unstructured":"Yang ES, Halabi S, Rothe M, et al: Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: Results from the TAPUR Study. JCO Precis Oncol 10.1200\/PO.22.00505","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_43_2","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR Study","author":"Gupta R","unstructured":"Gupta R, Meric-Bernstam F, Rothe M, et al: Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: Results from the TAPUR Study. JCO Precis Oncol 10.1200\/PO.22.00306","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_44_2","article-title":"Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the targeted agent and profiling utilization registry (TAPUR) Study","author":"Klute KA","unstructured":"Klute KA, Rothe M, Garrett-Mayer E, et al: Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: Results from the targeted agent and profiling utilization registry (TAPUR) Study. JCO Precis Oncol 10.1200\/PO.22.00191","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_45_2","article-title":"Palbociclib in patients with non-small-cell lung cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study","author":"Ahn ER","unstructured":"Ahn ER, Mangat PK, Garrett-Mayer E, et al: Palbociclib in patients with non-small-cell lung cancer with CDKN2A alterations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.20.00037","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_46_2","article-title":"Cobimetinib plus vemurafenib in patients with solid tumors with BRAF mutations: Results from the targeted agent and profiling utilization registry study","author":"Meric-Bernstam F","unstructured":"Meric-Bernstam F, Rothe M, Mangat PK, et al: Cobimetinib plus vemurafenib in patients with solid tumors with BRAF mutations: Results from the targeted agent and profiling utilization registry study. JCO Precis Oncol 10.1200\/PO.23.00385","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_47_2","article-title":"Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the targeted agent and profiling utilization registry Study","author":"Ahn ER","unstructured":"Ahn ER, Rothe M, Mangat PK, et al: Olaparib in patients with pancreatic cancer with BRCA1\/2 mutations: Results from the targeted agent and profiling utilization registry Study. JCO Precis Oncol 10.1200\/PO.23.00240","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_48_2","article-title":"Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the targeted agent and profiling utilization registry (TAPUR) Study","author":"Rohatgi N","unstructured":"Rohatgi N, Rothe M, Mangat PK, et al: Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: Results from the targeted agent and profiling utilization registry (TAPUR) Study. JCO Precis Oncol 10.1200\/PO.23.00279","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_49_2","article-title":"Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the targeted agent and profiling utilization registry Study","author":"Calfa CJ","unstructured":"Calfa CJ, Rothe M, Mangat PK, et al: Sunitinib in patients with breast cancer with FGFR1 or FGFR2 amplifications or mutations: Results from the targeted agent and profiling utilization registry Study. JCO Precis Oncol 10.1200\/PO.23.00513","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_50_2","article-title":"Regorafenib in patients with solid tumors with BRAF alterations: Results from the targeted agent and profiling utilization registry (TAPUR) Study","author":"Sahai V","unstructured":"Sahai V, Rothe M, Mangat PK, et al: Regorafenib in patients with solid tumors with BRAF alterations: Results from the targeted agent and profiling utilization registry (TAPUR) Study, JCO Precis Oncol 10.1200\/PO.23.00527","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02078"},{"key":"e_1_3_11_52_2","article-title":"Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the targeted agent and profiling utilization registry Study","author":"Srkalovic G","unstructured":"Srkalovic G, Rothe M, Mangat PK, et al: Talazoparib in patients with solid tumors with BRCA1\/2 mutation: Results from the targeted agent and profiling utilization registry Study. JCO Precis Oncol 10.1200\/PO.24.00026","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104545"},{"key":"e_1_3_11_54_2","article-title":"Palbociclib in patients with soft tissue sarcoma with CDK4 amplifications: Results from the targeted agent and profiling utilization registry Study","author":"Schuetze S","unstructured":"Schuetze S, Rothe M, Mangat PK, et al: Palbociclib in patients with soft tissue sarcoma with CDK4 amplifications: Results from the targeted agent and profiling utilization registry Study. JCO Precis Oncol 10.1200\/PO.24.00219","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_55_2","article-title":"Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: Results from the TAPUR Study","author":"Ahn ER","unstructured":"Ahn ER, Rothe M, Mangat PK, et al: Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: Results from the TAPUR Study. JCO Precis Oncol 10.1200\/PO.22.00609","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_56_2","article-title":"Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: Results from the targeted agent and profiling utilization registry Study","author":"Ganti AK","unstructured":"Ganti AK, Rothe M, Mangat PK, et al: Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: Results from the targeted agent and profiling utilization registry Study. JCO Precis Oncol 10.1200\/PO.23.00041","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_11_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_3_11_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3123"},{"key":"e_1_3_11_60_2","article-title":"Synthetic lethal Co-Mutations in DNA damage response pathways predict response to immunotherapy in pan-cancer","author":"Zhang L","unstructured":"Zhang L, Wang Y, Qiao R, et al: Synthetic lethal Co-Mutations in DNA damage response pathways predict response to immunotherapy in pan-cancer. JCO Precis Oncol 10.1200\/PO-25-00035","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_11_61_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1322187"},{"key":"e_1_3_11_62_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.4721"},{"key":"e_1_3_11_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7"},{"key":"e_1_3_11_64_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00091"},{"key":"e_1_3_11_65_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211058393"},{"key":"e_1_3_11_66_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_3_11_67_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0522"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-01205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:59:13Z","timestamp":1777579153000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-01205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1200\/PO-25-01205"],"URL":"https:\/\/doi.org\/10.1200\/po-25-01205","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2501205"}}